11/11
02:01 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/8
08:19 am
nbix
Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality [Yahoo! Finance]
Low
Report
Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality [Yahoo! Finance]
11/7
08:30 am
nbix
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
Low
Report
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules
11/5
04:01 pm
nbix
Neurocrine Biosciences to Participate at Investor Conferences in November
Medium
Report
Neurocrine Biosciences to Participate at Investor Conferences in November
11/4
08:42 am
nbix
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia [Yahoo! Finance]
Medium
Report
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia [Yahoo! Finance]
11/4
08:30 am
nbix
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
Medium
Report
Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules
11/4
08:25 am
nbix
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
Medium
Report
Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia
11/1
11:06 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
11/1
08:15 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $190.00 price target on the stock.
11/1
02:46 am
nbix
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024 [Yahoo! Finance]
Low
Report
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024 [Yahoo! Finance]
10/30
07:00 am
nbix
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
Medium
Report
Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance
10/29
08:00 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
10/17
10:38 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at BMO Capital Markets from $128.00 to $114.00. They now have a "market perform" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at BMO Capital Markets from $128.00 to $114.00. They now have a "market perform" rating on the stock.
10/16
04:13 pm
nbix
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]
Low
Report
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? [Yahoo! Finance]
10/10
09:36 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $155.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $155.00 price target on the stock.
10/10
08:02 am
nbix
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade) [Seeking Alpha]
Low
Report
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade) [Seeking Alpha]
10/9
04:01 pm
nbix
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
Low
Report
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results
10/4
11:36 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Royal Bank of Canada from $136.00 to $133.00. They now have a "sector perform" rating on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its price target lowered by analysts at Royal Bank of Canada from $136.00 to $133.00. They now have a "sector perform" rating on the stock.
10/3
06:33 am
nbix
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future? [Yahoo! Finance]
9/30
05:38 pm
nbix
Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market | DelveInsight [Yahoo! Finance]
Low
Report
Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market | DelveInsight [Yahoo! Finance]
9/30
05:16 pm
nbix
Neurocrine touts long-term effectiveness of Ingrezza for Huntington's disease chorea [Seeking Alpha]
Low
Report
Neurocrine touts long-term effectiveness of Ingrezza for Huntington's disease chorea [Seeking Alpha]
9/30
08:30 am
nbix
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
Low
Report
Neurocrine Biosciences Presents Interim Data Demonstrating Robust and Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 104 Irrespective of Antipsychotic Use
9/19
04:01 pm
nbix
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
Low
Report
Neurocrine Biosciences to Participate at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Virtual Summit
9/16
01:06 pm
nbix
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
Low
Report
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $155.00 price target on the stock.
9/13
05:39 am
nbix
Neurocrine's Phase II schizophrenia trial fails to meet primary endpoint [Yahoo! Finance]
Low
Report
Neurocrine's Phase II schizophrenia trial fails to meet primary endpoint [Yahoo! Finance]